AIDS Research and Treatment [21] M. M. Sajadi, N. Shakeri, R. Talwani, and R. R. Redﬁeld, “Hepatitis C infection in HIV-1 natural viral suppressors,” AIDS, vol. 24, no. 11, pp. 1689–1695, 2010. [22] S. Grabar, H. Selinger-Leneman, S. Abgrall, G. Pialoux, L. Weiss, and D. Costagliola, “Prevalence and comparative char- acteristics of long-term nonprogressors and HIV controller patients in the French Hospital Database on HIV,” AIDS, vol. 23, no. 9, pp. 1163–1169, 2009. [23] A. Petrucci, M. Dorrucci, M. B. Alliegro et al., “How many HIV-infected individuals may be deﬁned as long-term nonprogressors? A report from the Italian Seroconversion Study. Italian Seroconversion Study Group (ISS),” Journal of Acquired Immune Deﬁciency Syndromes & Human Retrovirol- ogy, vol. 14, no. 3, pp. 243–248, 1997. [24] O. Lambotte, F. Boufassa, Y. Madec et al., “HIV controllers: a homogeneous group of HIV-1-infected patients with spon- taneous control of viral replication,” Clinical Infectious Dis- eases, vol. 41, no. 7, pp. 1053–1056, 2005. [25] J. F. Okulicz, V. C. Marconi, M. L. Landrum et al., “Clinical outcomes of elite controllers, viremic controllers, and long- term nonprogressors in the US department of defense HIV natural history study,” Journal of Infectious Diseases, vol. 200, no. 11, pp. 1714–1723, 2009. [26] F. Boufassa, A. Saez-Cirion, J. Lechenadec et al., “CD4 dynamics over a 15 year-period among HIV controllers enrolled in the ANRS French Observatory,” PLoS ONE, vol. 6, no. 4, Article ID e18726, 2011. [27] P. W. Hunt, “Natural control of HIV-1 replication and long- term nonprogression: overlapping but distinct phenotypes,” Journal of Infectious Diseases, vol. 200, no. 11, pp. 1636–1638, 2009. [28] M. Saag and S. G. Deeks, “How do HIV elite controllers do what they do?” Clinical Infectious Diseases, vol. 51, no. 2, pp. 239–241, 2010. [29] B. Rode´s, C. Toro, E. Paxinos et al., “Diﬀerences in disease progression in a cohort of long-term non-progressors after more than 16 years of HIV-1 infection,” AIDS, vol. 18, no. 8, pp. 1109–1116, 2004. [30] G. H u¨tter and S. Ganepola, “Eradication of HIV by trans- plantation of CCR5-deﬁcient hematopoietic stem cells,” The Scientiﬁc World Journal, vol. 11, pp. 1068–1076, 2011. [31] A. Moses, J. Nelson, and G. C. Bagby, “The inﬂuence of human immunodeﬁciency virus-1 on hematopoiesis,” Blood, vol. 91, no. 5, pp. 1479–1495, 1998. [32] A. Marandin, A. Katz, E. Oksenhendler et al., “Loss of prim- itive hematopoietic progenitors in patients with human immunodeﬁciency virus infection,” Blood, vol. 88, no. 12, pp. 4568–4578, 1996. [33] S. D. Nielsen, P. Afzelius, S. Dam-Larsen et al., “Eﬀect of granulocyte colony-stimulating factor (G-CSF) in human immunodeﬁciency virus-infected patients: increase in num- bers of naive CD4 cells and CD34 cells makes G-CSF a candidate for use in gene therapy or to support antiretroviral therapy,” Journal of Infectious Diseases, vol. 177, no. 6, pp. 1733–1736, 1998. [34] S. D. Nielsen, D. R. Clark, M. Hutchings et al., “Treatment with granulocyte colony-stimulating factor decreases the capacity of hematopoietic progenitor cells for generation of lymphocytes in human immunodeﬁciency virus-infected persons,” Journal of Infectious Diseases, vol. 180, no. 6, pp. 1819–1826, 1999. [35] A. Alexaki and B. Wigdahl, “HIV-1 infection of bone marrow hematopoietic progenitor cells and their role in traﬃcking 9 and viral dissemination,” PLoS Pathogens, vol. 4, no. 12, Article ID e1000215, 2008. [36] C. C. Carter, A. Onafuwa-Nuga, L. A. McNamara et al., “HIV- 1 infects multipotent progenitor cells causing cell death and establishing latent cellular reservoirs,” Nature Medicine, vol. 16, no. 4, pp. 446–451, 2010. [37] S. D. Nielsen, D. L. Jeppesen, L. Kolte et al., “Impaired pro- genitor cell function in HIV-negative infants of HIV-positive mothers results in decreased thymic output and low CD4 counts,” Blood, vol. 98, no. 2, pp. 398–404, 2001. [38] S. Moir, J. Ho, A. Malaspina et al., “Evidence for HIV- associated B cell exhaustion in a dysfunctional memory B cell compartment in HIV-infected viremic individuals,” Journal of Experimental Medicine, vol. 205, no. 8, pp. 1797–1805, 2008. [39] D. Sauce, M. Larsen, S. Fastenackels et al., “HIV disease pro- gression despite suppression of viral replication is associated with exhaustion of lymphopoiesis,” Blood, vol. 117, no. 19, pp. 5142–5151, 2011. [40] D. C. Douek, R. A. Vescio, M. R. Betts et al., “Assessment of thymic output in adults after haematopoietic stem-cell transplantation and prediction of T-cell reconstitution,” The Lancet, vol. 355, no. 9218, pp. 1875–1881, 2000. [41] B. F. Haynes, M. L. Markert, G. D. Sempowski, D. D. Patel, and L. P. Hale, “The role of the thymus in immune recon- stitution in aging, bone marrow transplantation, and HIV-1 infection,” Annual Review of Immunology, vol. 18, pp. 529– 560, 2000. [42] L. Kolte, A. M. Dreves, A. K. Ersbøll et al., “Association between larger thymic size and higher thymic output in human immunodeﬁciency virus-infected patients receiving highly active antiretroviral therapy,” Journal of Infectious Diseases, vol. 185, no. 11, pp. 1578–1585, 2002. [43] M. D. Hazenberg, S. A. Otto, J. W. T. C. Stuart et al., “Increased cell division but not thymic dysfunction rapidly aﬀects the T-cell receptor excision circle content of the naive T cell population in HIV-1 infection,” Nature Medicine, vol. 6, no. 9, pp. 1036–1042, 2000. [44] D. C. Douek, R. D. McFarland, P. H. Keiser et al., “Changes in thymic function with age and during the treatment of HIV infection,” Nature, vol. 396, no. 6712, pp. 690–695, 1998. [45] B. Autran, G. Carcelain, T. S. Li et al., “Positive eﬀects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease,” Science, vol. 277, no. 5322, pp. 112–116, 1997. [46] S. J. Potter, C. Lacabaratz, O. Lambotte et al., “Preserved central memory and activated eﬀector memory CD4+ T-cell subsets in human immunodeﬁciency virus controllers: an ANRS EP36 study,” Journal of Virology, vol. 81, no. 24, pp. 13904–13915, 2007. [47] G. Marchetti, A. Riva, M. Cesari et al., “HIV-infected long- term nonprogressors display a unique correlative pattern between the interleukin-7/interleukin-7 receptor circuit and T-cell homeostasis,” HIV Medicine, vol. 10, no. 7, pp. 422– 431, 2009. [48] S. J. Westrop, N. A. Qazi, J. Pido-Lopez et al., “Transient nature of long-term nonprogression and broad virus-speciﬁc proliferative T-cell responses with sustained thymic output in HIV-1 controllers,” PLoS ONE, vol. 4, no. 5, Article ID e5474, 2009. [49] R. H. T. Fang, E. Khatissian, V. Monceaux et al., “Disease pro- gression in macaques with low SIV replication levels: on the relevance of TREC counts,” AIDS, vol. 19, no. 7, pp. 663–673, 2005.